AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12038495 — intervention group
Group type: EXPERIMENTAL
Intervention: Misspellings made by writers in a short essay
Number of subjects: 0
Study 10844630 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% TPD
Number of subjects: 0
Study 10844630 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% TPD
Number of subjects: 0
Study 10844630 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% TPD
Number of subjects: 0
Study 10844630 — intervention group
Group type: COMPARATOR
Intervention: APD (Group I)
Number of subjects: 0
Study 10844630 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% TPD (Group II)
Number of subjects: 0
Study 10844630 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% TPD (Group II)
Number of subjects: 0
Study 10844630 — intervention group
Group type: COMPARATOR
Intervention: APD (Group II)
Number of subjects: 0
Study 9279669 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophobic IOLs (specific types not detailed)
Number of subjects: 0
Study 9279669 — intervention group
Group type: COMPARATOR
Intervention: Hydrophilic IOLs (specific types not detailed)
Number of subjects: 0
Study 2054701 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.3 to 0.5 mg/kg) combined with atropine sulfate (0.015 mg/kg)
Number of subjects: 40
Study 2054701 — intervention group
Group type: COMPARATOR
Intervention: Placebo (injectable water) combined with atropine sulfate (0.015 mg/kg)
Number of subjects: 40
Study 2054701 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 40
Study 2054701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6356966 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline inhalations (31 + 31 + 63 + 125 + 250 micrograms) from a pressurized aerosol with a 750 ml spacer
Number of subjects: 12
Study 6356966 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not explicitly mentioned but implied as part of the double-blind design)
Number of subjects: 12
Study 31726485 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure
Number of subjects: 1101
Study 31726485 — intervention group
Group type: COMPARATOR
Intervention: Sham continuous positive airway pressure
Number of subjects: 1101
Study 30999058 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored smoking-cessation intervention delivered 100% through text messaging (TMQ)
Number of subjects: 0
Study 30999058 — intervention group
Group type: COMPARATOR
Intervention: Non-smoking-related text messages (Mojo)
Number of subjects: 0
Study 28137609 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary nitrate load (300 mg) by highly concentrated beetroot juice (BJ)
Number of subjects: 17
Study 28137609 — intervention group
Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 17
Study 25869625 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Remote Monitoring and Management System (DRMS)
Number of subjects: 98
Study 25869625 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 98
Study 23131174 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo® Wii Balance Board exercises (Group A)
Number of subjects: 71
Study 23131174 — intervention group
Group type: COMPARATOR
Intervention: Control group with only two elected exercises (Group B)
Number of subjects: 71
Study 21397780 — intervention group
Group type: COMPARATOR
Intervention: 400-mg rufinamide tablet (reference)
Number of subjects: 24
Study 21397780 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of rufinamide suspension (40 mg/mL) at 1800 rpm
Number of subjects: 24
Study 21397780 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of rufinamide suspension (40 mg/mL) at 2100 rpm
Number of subjects: 24
Study 21397780 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of rufinamide suspension (40 mg/mL) at 3000 rpm
Number of subjects: 24
Study 18444817 — intervention group
Group type: COMPARATOR
Intervention: 1.5 g of cefuroxime 10‐30 min before inflation of the tourniquet and placebo 10 min before release of the tourniquet (standard arm)
Number of subjects: 908
Study 18444817 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo 10‐30 min before inflation of the tourniquet and 1.5 g of cefuroxime 10 min before release of the tourniquet (experimental arm)
Number of subjects: 908
Study 16557208 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐MIBI brain SPECT and proton magnetic resonance spectroscopy (1H‐MRS)
Number of subjects: 30
Study 16557208 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐MIBI brain SPECT
Number of subjects: 30
Study 15724755 — intervention group
Group type: EXPERIMENTAL
Intervention: Concise Light Cured White Sealant applied without vibration
Number of subjects: 36
Study 15724755 — intervention group
Group type: EXPERIMENTAL
Intervention: Concise Light Cured White Sealant applied with vibration
Number of subjects: 36
Study 15724755 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond Adhesive applied, then Concise Light Cured White Sealant applied without vibration
Number of subjects: 36
Study 15724755 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond Adhesive applied, then Concise Light Cured White Sealant applied with vibration
Number of subjects: 36
Study 15724755 — intervention group
Group type: EXPERIMENTAL
Intervention: Concise Light Cured White Sealant applied without vibration, then Z‐100 composite burnished over sealant and light‐cured
Number of subjects: 36
Study 15724755 — intervention group
Group type: EXPERIMENTAL
Intervention: Concise Light Cured White Sealant applied with vibration, then Z‐100 composite burnished over sealant and light‐cured
Number of subjects: 36
Study 11097670 — intervention group
Group type: COMPARATOR
Intervention: Needle only
Number of subjects: 30
Study 11097670 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5%
Number of subjects: 30
Study 11097670 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5%
Number of subjects: 30
Study 11097670 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% with dexamethasone 0.13 mg/mL
Number of subjects: 30
Study 11097670 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% with dexamethasone 0.13 mg/mL
Number of subjects: 30
Study 9315064 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary therapy with tamoxifen alone (n=160)
Number of subjects: 184
Study 9315064 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastectomy and postoperative tamoxifen (n=53)
Number of subjects: 184
Study 9315064 — intervention group
Group type: COMPARATOR
Intervention: Primary surgery (104 mastectomy; 27 wide local excision) without adjuvant tamoxifen (n=131)
Number of subjects: 184
Study 9315064 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional relapse treated with surgery, radiotherapy or endocrine manipulation
Number of subjects: 184
Study 8336864 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex (goserelin acetate), 3.6 mg every 28 days by subcutaneous injection
Number of subjects: 315
Study 8336864 — intervention group
Group type: COMPARATOR
Intervention: Danazol, 400 mg orally twice daily for 24 weeks
Number of subjects: 315
Study 3528119 — intervention group
Group type: EXPERIMENTAL
Intervention: Choledyl SA
Number of subjects: 10
Study 3528119 — intervention group
Group type: COMPARATOR
Intervention: Theo-Dur
Number of subjects: 10
Study 3276422 — intervention group
Group type: COMPARATOR
Intervention: Standard ligament release alone
Number of subjects: 50
Study 3276422 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive interfascicular neurolysis
Number of subjects: 50
Study 29689693 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (10 or 20mg)
Number of subjects: 602
Study 29689693 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine (60mg)
Number of subjects: 602
Study 29689693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 602
Study 28057058 — intervention group
Group type: EXPERIMENTAL
Intervention: Lian-Ju-Gan-Mao capsules (LJGMC) high-dose group
Number of subjects: 240
Study 28057058 — intervention group
Group type: EXPERIMENTAL
Intervention: Lian-Ju-Gan-Mao capsules (LJGMC) medium-dose group
Number of subjects: 240
Study 28057058 — intervention group
Group type: EXPERIMENTAL
Intervention: Lian-Ju-Gan-Mao capsules (LJGMC) low-dose group
Number of subjects: 240
Study 28057058 — intervention group
Group type: COMPARATOR
Intervention: Placebo-matched group
Number of subjects: 240
Study 26203738 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingerboarding (FB)
Number of subjects: 23
Study 26203738 — intervention group
Group type: COMPARATOR
Intervention: Bouldering (BL)
Number of subjects: 23
Study 23987903 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive esophagectomy
Number of subjects: 114
Study 23987903 — intervention group
Group type: COMPARATOR
Intervention: Open esophagectomy
Number of subjects: 114
Study 21050796 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular sunlight exposure (3231 min/year)
Number of subjects: 324
Study 21050796 — intervention group
Group type: COMPARATOR
Intervention: Usual lifestyle
Number of subjects: 324
Study 18697849 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip protectors worn on either the right or left hip
Number of subjects: 580
Study 18697849 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hip protectors)
Number of subjects: 580
Study 16596114 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX): 1 hour of cycling at 63.1+/‐6% VO2peak (TRI) and 61+/‐5.1% VO2peak (REC)
Number of subjects: 14
Study 16596114 — intervention group
Group type: COMPARATOR
Intervention: Rest (RE): 1 hour of sitting
Number of subjects: 14
Study 15587400 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 32
Study 15587400 — intervention group
Group type: COMPARATOR
Intervention: Conventional IVF
Number of subjects: 32
Study 15587400 — intervention group
Group type: COMPARATOR
Intervention: IVF
Number of subjects: 32
Study 12575402 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenkang injection (SKI)
Number of subjects: 0
Study 12575402 — intervention group
Group type: COMPARATOR
Intervention: Benazepril
Number of subjects: 0
Study 9260237 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort (DFZ)
Number of subjects: 40
Study 9260237 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (PDN)
Number of subjects: 40
Study 7984593 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant endovascular irradiation of blood with He‐Ne laser (8-10 daily sessions lasting 30 minutes)
Number of subjects: 48
Study 3104873 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubly labeled water (DLW)
Number of subjects: 9
Study 3104873 — intervention group
Group type: COMPARATOR
Intervention: RGE (Respiratory Gas Exchange)
Number of subjects: 9
Study 29119483 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 66
Study 29119483 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 66
Study 29916668 — intervention group
Group type: EXPERIMENTAL
Intervention: Maylard incision
Number of subjects: 81
Study 29916668 — intervention group
Group type: COMPARATOR
Intervention: Pfannenstiel incision
Number of subjects: 81
Study 29916668 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 81
Study 24600214 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve blocks (PNBs) with propofol sedation
Number of subjects: 213
Study 24600214 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia with combined propofol and remifentanil
Number of subjects: 213
Study 22715910 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge and community educational videos (scientific vs. colloquial)
Number of subjects: 92
Study 22715910 — intervention group
Group type: COMPARATOR
Intervention: Pictorial pamphlet
Number of subjects: 92
Study 20435291 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy supplementation
Number of subjects: 39
Study 20435291 — intervention group
Group type: COMPARATOR
Intervention: Casein placebo
Number of subjects: 39
Study 18603505 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (50 micrograms every 4 hours for a maximum of four doses)
Number of subjects: 84
Study 18603505 — intervention group
Group type: COMPARATOR
Intervention: Control (conservative management)
Number of subjects: 84
Study 15729173 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental arginine and canola oil (omega-3 and omega-9 fatty acids) twice daily
Number of subjects: 147
Study 12746761 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro (LP)
Number of subjects: 143
Study 12746761 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide (GB)
Number of subjects: 143
Study 11046211 — intervention group
Group type: EXPERIMENTAL
Intervention: HES200 (15 ml/kg)
Number of subjects: 22
Study 11046211 — intervention group
Group type: COMPARATOR
Intervention: HES70 (15 ml/kg)
Number of subjects: 22
Study 9075745 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative multimodality therapy (Group 1) including seven cycles of 5-fluorouracil (FU)/leucovorin (LV) chemotherapy and radiation therapy (5,040 cGy) before surgery.
Number of subjects: 116
Study 9075745 — intervention group
Group type: COMPARATOR
Intervention: Postoperative multimodality therapy (Group 2) including the same chemotherapy and radiation therapy after surgery.
Number of subjects: 116
Study 9075745 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative multimodality therapy (Group 1).
Number of subjects: 116
Study 9075745 — intervention group
Group type: COMPARATOR
Intervention: Postoperative multimodality therapy (Group 2).
Number of subjects: 116
Study 9075745 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group 1 and Group 2).
Number of subjects: 116
Study 8422745 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol metered dose inhaler (0.4 mg)
Number of subjects: 16
Study 8422745 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol dry powder capsules (0.4 mg)
Number of subjects: 16
Study 8422745 — intervention group
Group type: EXPERIMENTAL
Intervention: Colforsin dry powder capsules (10.0 mg)
Number of subjects: 16
Study 8422745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3024826 — intervention group
Group type: EXPERIMENTAL
Intervention: BTOC (carmustine, thiotepa, vincristine, and cyclophosphamide)
Number of subjects: 428
Study 3024826 — intervention group
Group type: COMPARATOR
Intervention: CAV (cyclophosphamide, doxorubicin, and vincristine)
Number of subjects: 428
Study 3024826 — intervention group
Group type: EXPERIMENTAL
Intervention: BTOC followed by multiple-site irradiation
Number of subjects: 428
Study 3024826 — intervention group
Group type: COMPARATOR
Intervention: CAV followed by multiple-site irradiation
Number of subjects: 428
Study 3024826 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-field irradiation consolidation
Number of subjects: 428
Study 30913065 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual-spatial neglect (VSN) group
Number of subjects: 33
Study 30913065 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-VSN group
Number of subjects: 33
Study 30913065 — intervention group
Group type: EXPERIMENTAL
Intervention: VSN group
Number of subjects: 33
Study 30913065 — intervention group
Group type: EXPERIMENTAL
Intervention: VSN group and Non-VSN group
Number of subjects: 33
Study 28391875 — intervention group
Group type: EXPERIMENTAL
Intervention: MAT9001
Number of subjects: 42
Study 28391875 — intervention group
Group type: COMPARATOR
Intervention: EPA-EE
Number of subjects: 42
Study 26200232 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusion protocol
Number of subjects: 2016
Study 23470806 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus cilostazol (cilo)
Number of subjects: 20
Study 23470806 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone (non-cilo group)
Number of subjects: 20
Study 21946218 — intervention group
Group type: EXPERIMENTAL
Intervention: Single site umbilical laparoscopic appendectomy
Number of subjects: 360
Study 21946218 — intervention group
Group type: COMPARATOR
Intervention: Standard 3-port laparoscopic appendectomy
Number of subjects: 360
Study 19111610 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant (AO) supplementation (200 IU of vitamin E and 500 mg ascorbic acid)
Number of subjects: 0
Study 19111610 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 0
Study 16641947 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocognitive tests administered (11 tests resulting in 24 individual scores)
Number of subjects: 1493
Study 16641947 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-factor model comprised of five domain scores
Number of subjects: 1493
Study 16641947 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with negative symptom severity
Number of subjects: 1493
Study 16641947 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with positive symptom severity
Number of subjects: 1493
Study 16641947 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite score derived from individual factors
Number of subjects: 1493
Study 15448595 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior approach
Number of subjects: 59
Study 15448595 — intervention group
Group type: COMPARATOR
Intervention: Lateral approach
Number of subjects: 59
Study 11399983 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir (APV) 450 mg with Ritonavir (RTV) 300 mg
Number of subjects: 0
Study 11399983 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir (APV) 450 mg with Ritonavir (RTV) 100 mg
Number of subjects: 0
Study 11399983 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir (APV) 900 mg with Ritonavir (RTV) 100 mg
Number of subjects: 0
Study 11399983 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir (RTV) co-administration with APV
Number of subjects: 0
Study 11399983 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV) 300 mg
Number of subjects: 0
Study 11399983 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV) 100 mg
Number of subjects: 0
Study 9757514 — intervention group
Group type: EXPERIMENTAL
Intervention: Hop-valerian preparation
Number of subjects: 0
Study 9757514 — intervention group
Group type: COMPARATOR
Intervention: Benzodiazepine preparation
Number of subjects: 0
Study 7914050 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (2, 4 and 6 mg)
Number of subjects: 0
Study 7914050 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (50 mg)
Number of subjects: 0
Study 7914050 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride (100 and 150 mg)
Number of subjects: 0
Study 2905152 — intervention group
Group type: EXPERIMENTAL
Intervention: levocabastine (200 micrograms)
Number of subjects: 10
Study 2905152 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 10
Study 28513238 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise intervention
Number of subjects: 19
Study 28513238 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge and understanding of physical exercise
Number of subjects: 19
Study 28513238 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement of staff and family carers
Number of subjects: 19
Study 28187725 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based cancer aftercare intervention for 6 months
Number of subjects: 462
Study 28187725 — intervention group
Group type: COMPARATOR
Intervention: Control group (access after 12 months)
Number of subjects: 462
Study 26189601 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter sleep duration
Number of subjects: 1008
Study 26189601 — intervention group
Group type: EXPERIMENTAL
Intervention: Food responsiveness (FR) mediation
Number of subjects: 1008
Study 23458045 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient haemorrhoidectomy
Number of subjects: 208
Study 23458045 — intervention group
Group type: COMPARATOR
Intervention: Inpatient haemorrhoidectomy
Number of subjects: 208
Study 21296010 — intervention group
Group type: EXPERIMENTAL
Intervention: Televideoconferencing (TVC)
Number of subjects: 78
Study 19426757 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported home-based walking during the 12-week RCT
Number of subjects: 38
Study 16989189 — intervention group
Group type: EXPERIMENTAL
Intervention: 633-nm and 830-nm LED treatments
Number of subjects: 36
Study 15259281 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/day of tricalcium phosphate (TCP)
Number of subjects: 153
Study 15259281 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/day of ossein‐hydroxyapatite (OHC)
Number of subjects: 153
Study 15259281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 11199708 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermafil
Number of subjects: 160
Study 11199708 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral condensation
Number of subjects: 160
Study 11199708 — intervention group
Group type: EXPERIMENTAL
Intervention: McSpadden
Number of subjects: 160
Study 11199708 — intervention group
Group type: EXPERIMENTAL
Intervention: All techniques
Number of subjects: 160
Study 9264275 — intervention group
Group type: EXPERIMENTAL
Intervention: High vegetable, low fat diet intervention
Number of subjects: 79
Study 9264275 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 79
Study 8570762 — intervention group
Group type: EXPERIMENTAL
Intervention: Brofaromine (selective and reversible inhibitor of monoamine oxidase type A)
Number of subjects: 0
Study 8570762 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (standard tricyclic compound)
Number of subjects: 0
Study 10148140 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextranomer paste (Debrisan)
Number of subjects: 40
Study 10148140 — intervention group
Group type: COMPARATOR
Intervention: Polyvinylpyrrolidone (control)
Number of subjects: 40
Study 105442 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 0
Study 105442 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapeutic agents
Number of subjects: 0
Study 31872213 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted HDL-C (per standard deviation increase)
Number of subjects: 181677
Study 31872213 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted triglycerides
Number of subjects: 181677
Study 31872213 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted total cholesterol
Number of subjects: 181677
Study 31872213 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted LDL-C
Number of subjects: 181677